Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
| Autor: | Tokatlian T; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Asuelime GE; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Mock JY; A2 Biotherapeutics Inc, Agoura Hills, California, USA., DiAndreth B; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Sharma S; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Toledo Warshaviak D; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Daris ME; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Bolanos K; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Luna BL; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Naradikian MS; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Deshmukh K; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Hamburger AE; A2 Biotherapeutics Inc, Agoura Hills, California, USA., Kamb A; A2 Biotherapeutics Inc, Agoura Hills, California, USA akamb@a2biotherapeutics.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jan; Vol. 10 (1). |
| DOI: | 10.1136/jitc-2021-003826 |
| Abstrakt: | Background: Mesothelin (MSLN) is a classic tumor-associated antigen that is expressed in lung cancer and many other solid tumors. However, MSLN is also expressed in normal mesothelium which creates a significant risk of serious inflammation for MSLN-directed therapeutics. We have developed a dual-receptor (Tmod™) system that exploits the difference between tumor and normal tissue in a subset of patients with defined heterozygous gene loss (LOH) in their tumors. Methods: T cells engineered with the MSLN CAR Tmod construct described here contain (1) a novel MSLN-activated CAR and (2) an HLA-A*02-gated inhibitory receptor (blocker). A*02 binding is intended to override T-cell cytotoxicity, even in the presence of MSLN. The Tmod system is designed to treat heterozygous HLA class I patients, selected for HLA LOH. When A*02 is absent from tumors selected for LOH, the MSLN Tmod cells are predicted to mediate potent killing of the MSLN(+)A*02(-) malignant cells. Results: The sensitivity of the MSLN Tmod cells is comparable with a benchmark MSLN CAR-T that was active but toxic in the clinic. Unlike MSLN CAR-T cells, the Tmod system robustly protects surrogate "normal" cells even in mixed-cell populations in vitro and in a xenograft model. The MSLN CAR can also be paired with other HLA class I blockers, supporting extension of the approach to patients beyond A*02 heterozygotes. Conclusions: The Tmod mechanism exemplified by the MSLN CAR Tmod construct provides an alternative route to leverage solid-tumor antigens such as MSLN in safer, more effective ways than previously possible. Competing Interests: Competing interests: All authors are current or former employees and shareholders of A2 Biotherapeutics, Inc. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|